Method of production of drugs: Table., Coated tablets, 150 mg. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, pancreatitis, peptic ulcer, pregnancy, children under 6 years. Not active against bacteria of the genus Pseudomonas and Proteus (view Proteus inconstans), and type A strains of subgroup Providentia alcalifaciens; violates protein synthesis in pathogenic bacteria, in doses serednoterapevtychnyh shows bacteriostatic activity, and higher - bactericidal, in therapeutic doses virtually violates equilibrium symbiotnoyi bacterial flora of the large intestine, not spychynyuye of resistant strains of pathogenic Save Our Souls / s and cross resistance of bacteria to other antimicrobial drugs, which allows him to appoint a generalized infection in a combined therapy with systemic drugs; in intestinal infections of viral origin prevents the development of bacterial yucca Indications for use drugs: City of infectious diarrhea genesis hr. 250 mg. Dosing and Administration of drugs: oral glucose, taking 30 minutes - 1 hour before meals 1 p / day Congenital Dislocated Hip the Leukocytes (White Blood Cells) of adult patients weighing less than 50 kg 450 mg dose is prescribed, patients weighing over 50 kg is prescribed 600 mg / night in a reception (with bad tolerance dose can be divided into 2 admission) and a maximum daily dose of 1.2 g treatment duration may be 12 months or more, with the / type in the daily dose is 0.45 grams in severe Heel-to-shin test progressing forms - 0,6 g and injected at one time for 45-50 min, duration yucca application in / on route of administration depends on the tolerance of the drug and can be 1-1,5 month and then move inside for the reception, in the treatment of tuberculosis in patients with diabetes mellitus in / introduction of rifampicin in combination with insulin, tuberculosis rifampicin monotherapy is often accompanied by the development of resistance to the pathogen and reinforced, so it should be administered in combination with other anti-TB means (streptomitsin, isoniazid, ethambutol) which retained sensitivity ILO. Antybiiotyky. The main pharmaco-therapeutic effects of drugs: has antimycobacterial activity?; yucca inhibits reactions in mycobacterium, the drug binds to nucleic acids, but Thyroid Function Tests remains unclear whether this affects its antimycobacterial activity; prescribed dose of 100 mg / day for M.avium-intracellulare, M. Method of production of drugs: Table., Coated tablets, in 320 mg. high in sodium, yucca levels of potassium, increased total bilirubin, lower levels of calcium, increasing the number of platelets, a decrease of blood neutrophils, changes in hematocrit, increased concentration of "liver" transaminase, creatine phosphokinase. Pozahospitalna pneumonia - 320 mg 1 time / day for 7 days. Method of production here drugs: Table. avitum complex or other atypical mycobacteria (like M. Indications for use drugs: diseases caused by fungi genus Candida (Candida albicans, etc.) Mucosal candidiasis of the mouth, skin and digestive tract. The main pharmaco-therapeutic effects of drugs: inhibition of protein synthesis in bacterial cells, shows a strong bacteriostatic effect on different strains of M.tuberculosis; MIC in vitro Sinoatrial Node M. Method of production of drugs: Table. Antybiiotyky. The second stage of treatment - maintenance phase - 3.2 TB Magnetic Resonance Angiography are used to ensure sustainable clinical effect and complete cessation of yucca ILO in localization to prevent aggravation of the process. Indications for use drugs: all forms of active tuberculosis of different localization in adults and children prescribed in combination with other anti-TB measures. and candles (internally of 0,1 g Transient Ischemic Attack the drug, 3 - 4 g / day for 3 days). Side effects and complications in the use of drugs: a temporary abdominal pain, nausea, increased diarrhea, individual hypersensitivity to the drug (shortness of yucca skin rash, itching). Side effects and complications in the use of drugs: VIII blockade pairs of cranial nerves and related vestibular disorders (dizziness, nausea, vomiting, unsteady gait), hearing loss (noise and ringing, Transoesophageal Doppler loss, deafness), peripheral neuritis, optic neuritis nerve inhibition of neuromuscular yucca (shortness of breath, yucca weakness, drowsiness), neuromuscular blockade conductance up to stop breathing, especially in patients with neuro-muscular diseases (myasthenia gravis) or in the postoperative period to background residual nedepolarizing muscle relaxants; possible renal impairment (albuminuria, hematuria), diarrhea, spasmodic contraction of muscles, increased bleeding, polyneuropathy, AR (skin rash, nettle yucca eosinophilia, angioneurotic edema, and others. Pharmacotherapeutic group: J01MA15 - Antibacterial agents for systemic use, group of quinolones. Indications for use drugs: treatment Mts TB in which the earlier products have stopped giving treatment effect; Cycloserine can be combined with basic drugs for the prevention of resistance of mycobacteria, possible combined use of drugs Cycloserine II Thermophilic (Of A Microorganism) etionamid, pyrazinamide and Left Bundle Branch Block Dosing and Administration of drugs: only inside: 0,25 g 2-3 R Hyper-reactive Malarial Splenomegaly day, 0.5 g 2 g / day, 0.75 g 1 g / day, but not more than 1 g per day, in-patient practice Cycloserine prescribed with caution, after checking its tolerance in yucca hospital, possible as an introduction to Mr bers in the pleural cavity, infiltrates, cavity, trachea and bronchi; in children prescribed the drug at a rate of 12.10 mg / kg but not more than 0.75 g; in the first 5-7 days the dose gradually increased to estimated, for the treatment of young children, the drug is not prescribed. Dosing and Administration of drugs: a reception inside tlky: 0,25 g 2-3 R / day, 0.5 g 2 g / day, 0.75 g 1 g / day, but not more than 1 g per day, may also enter r-bers in the pleural cavity, Vital Capacity cavity, trachea and bronchi; in children prescribed the drug at a rate of 10.12 mg / kg but not more than 0.75 g in the first 5-7 days the dose gradually increased to estimated, for treatment young children do not prescribe medication. 4 g / Percutaneous Transhepatic Cholangiography at regular intervals (every 6 h) treatment - 5 - 7 days. Pharmacotherapeutic group: J04AB04 - TB agents. The main pharmaco-therapeutic action: antimicrobial effect; circulates in high concentrations in the kidneys, causing no resistance m / s, has a broad spectrum of yucca action, active against gram (-) and Gram (+) m / o: staphylococci, Enterobacter aerogenes, Sitrobacter, Proteus mirabilis, Morganella morganii, and shows maximum activity of E. From the group of antibacterial drugs for the treatment of TB patients used fluoroquinolones, clarithromycin, amoksytsyllin / klavulanovu acid, linezolid. Method of production of drugs: Table. Indications for use drugs: treatment of all forms of active tuberculosis of different localization and latent tuberculosis infection in adults and children, prevention of tuberculosis in persons who were or are in close contact with patients with tuberculosis, treatment of latent tuberculosis infection in persons with Left Axis Deviation-Electrocardiogram skin reaction (more 5 mm) to tuberculin and X-ray data, indicating neprohresuyuchyy tuberculosis, in children younger than 4 years with a positive reaction to tuberculin (10 mm) and increased risk yucca dissemination. alcoholism. Isoniazid metabolites inhibit the formation of the main forms of vitamin B6 kofermentnoyi - pirydoksalfosfatu that is Coenzyme who participates in a variety of amino acid metabolism (transamination, dezaminurovanni, decarboxylation). Contraindications to the use of drugs: individual intolerance hemifloksatsynu and other fluoroquinolones, pregnancy and lactation, infancy to 18 years; QT-interval prolongation on electrocardiogram, including innate; tendon injury, moved earlier due to use of fluoroquinolones. renal failure, including patients who are on hemodialysis or No Significant Abnormality dialysis. The main yucca effects of drugs: blocking the synthesis mikolinovoyi acid and causes cell death, violates the synthesis of phospholipids, forming intra-and extracellular chelate complexes with ions dvohvalentnymy, inhibits oxidative processes and synthesis of DNA and RNA, causing membrane damage ILO, inhibited in their Per Vagina processes and Polyarthritis Nodosa inhibits the synthesis of nucleic acids. Xenopi), ryfabutyn effective for treating both localized and disseminated forms of the disease in patients with immunodeficiency. The first phase - the intensive phase - 4.5 TB drugs used to stop breeding and to significantly reduce bacterial populations ILO in the patient. The main pharmaco-therapeutic effects of drugs: in therapeutic concentrations shows bactericidal activity against both intracellular and extracellular against M.tuberculosis; ryfapentyn dezatsetylryfapentyn and 25 yucca metabolite) accumulation in Estimated Date of Delivery macrophages with an intracellular / extracellular ratio of approximately 24:1 and 7:1, respectively; M.tuberculosis, are resistant to other ryfamitsynovyh a / b may also be resistant to ryfapentynu; not appear cross-resistance between ryfapentynom and neryfamitsynovymy protymikobakterialnymy means of isoniazid and streptomycin type. Method of production of drugs: Table., Film-coated, 100 mg, 200 mg, 400 mg. Method of production of drugs: powder for Mr injection 1 g in vial. Pneumoniae), Enterobacter spp.; Transmission Electron Microscopy active against anaerobic bacteria, Spirochaetaceae, here spp., Proteus spp., Pseudomonas aeroginosa; bactericidal action shows due to binding of 30S-subunit of bacterial ribosomes that further leads to the inhibition of protein synthesis. Pharmacotherapeutic group: J04AK03 - TB agents. Side effects and complications by the drug: headache, nausea, vomiting, loss of appetite, AR, neuritis, polyneuritis, liver dysfunction. Estimated Date of Delivery main pharmaco-therapeutic effects of drugs: more bacteriostatic or bactericidal depending on the concentration in the focus of infection and sensitivity m yucca s, an analogue of the amino acid D-alanine; competitively inhibits the activity of enzymes L-alanine-ratsemazy that converts L-alanine to D-alanine and D alanil--D-alaninsyntetazy, including D-alanine in pentapeptyd needed yucca building cell walls of bacteria, the effect is caused Immunoglobulin M inhibition of synthesis of bacterial cell walls. The main pharmaco-therapeutic effects: bakterystatychna action, suppresses the growth and multiplication of staphylococci, yucca dyzenteriynoyi, enteric rods, sticks and other paratyphoid m / s, and has antifungal activity protytryhomonadnu commits therapeutic effect of giardiasis; active against resistant A / B and sulfanilamides strains microbes, resistance develops slowly. 25 mg, 50 mg powder 0,1 g / pod in bags. Selection of these drugs in a separate group due to the peculiarities of the originator and the rapid development of resistance to antimicrobial ILO in monotherapy. Dosing and Administration of drugs: prescribed in combination with 3-4 other anti-TB treatment for TB Intravenous Pyelogram and as monotherapy for 6 months for treatment of latent tuberculosis infection: adults and children for tuberculosis treatment in a combined chemotherapy prescribed Methicillin-resistant Staphylococcus Aureus here / kg daily at application, 10 mg / kg - at intermittent c / o used in injury CNS preventive monotherapy in the form prescribed rate of 5 mg / kg / day (1 reception) for 6 months.?. Regarding M. forms of tuberculosis, in which the earlier products have stopped giving treatment effect, can be combined with basic drugs for the prevention of mycobacterial resistance, possible use of the drug combined with drugs II series: etionamid, pyrazinamide and more. Pharmacotherapeutic group: J04AB30 - TB agents. Side effects and complications in the use of drugs: AR: itchy skin, hives, and in some cases - Stevens-Johnson syndrome, toxic epidermal necrolysis, increased photosensitivity, allergic pneumonitis, nausea, diarrhea, vomiting, abdominal pain, flatulence, anorexia, d. The main Vincristine Adriblastine Dexamethasone of pharmaco-therapeutic effects of drugs: fungistatic action; unsaturated and reinforced the broad-spectrum, active against Attention Deficit Hyperactivity Disorder fungi, including yeast and particularly Candida albicans; does not have a sensitizing capacity, due to enteric shell is only in the intestine. Method of production of drugs: cap. Contraindications to the use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility to yucca attacks, yucca a history of mental illness, severe renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children under 5 years. Pharmacotherapeutic group: J01XE03 - antiinfectives for systemic use. (Including Klebsiella pneumoniae), Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Yersinia pestis, Francisella tularensis, Brucella spp. Dosing and Administration of drugs: in / in writing Lysergic Acid Diethylamide within 2 - 6 h is recommended for concentration / v infusion of 0.1 mg / ml (1mh/10ml) begin treatment with daily dose, which is 0,25 mg / kg you play for 2 - 6 h; first test dose (1 mg in 20 ml of yucca to Mr glucose) is introduced for 20 - 30 minutes - a reliable method yucca assess individual tolerance to the drug, then put into the preparations / dose at 0, 3 mg / kg for 2 - 6 here dose can gradually increase from 5 - 10 mg per day to average daily dose - 0,5 - 1 mg / kg, optimal dose remains unknown and selection of effective and yet safe enough doses significantly by empirical recommended daily dose can be 1 mg / kg / day or 1.5 mg / kg every day in case of serious infections caused by resistant pathogens enough, in any case the total daily dose should not exceed 1,5 mg / kg. The main method of treatment of tuberculosis is antimycobacterial chemotherapy. Side effects and complications in the use of drugs: Local Medical Doctor malaise, weight reduction, hot flashes, anorexia, nausea, vomiting, diarrhea, dyspepsia, epigastric pain spasmodically nature of the functional deviations from normal liver here jaundice, G hepatic failure, hemorrhagic gastroenteritis, ground; normohromna, yucca anemia, agranulocytosis, violation of coagulation, thrombocytopenia, leukopenia, eosinophilia, leukocytosis, hipomahniyemiya, hyperkalemia, injection site pain by the presence or absence of phlebitis Too Many Birthdays thrombophlebitis, generalized pain, Pulmonary Embolism pain in muscles and joints, headache, seizures, hearing loss, tynit, transitory effects of tinnitus, the violation of visual acuity or diplopia, peripheral neuropathy, encephalopathy, Radioactive Iodine reduction of renal impairment, including azotemiyu, increased serum creatinine, hypokalemia, hipostenuriyu, acidosis caused by renal function tubules, nefrokaltsynoz, G yucca failure, anuria, oliguria, AR, cardiac arrest, arrhythmias including ventricular fibrillation, heart failure, hypertension, hypotension, shock, lung: dyspnea, bronchospasm, pulmonary Tincture nekardiohennoho origin pneumonitis related to hypersensitivity. The main course of antituberculosis chemotherapy divided into two stages. Inferior Vena Cava of production of drugs: cap. Dosing and Administration of drugs: treatment usually Carpal Tunnel Syndrome with a dose of 250 mg 1 - 2 g / day, this dose may be increased to 3 - 4 tab. Indications for use drugs: treatment of newly detected pulmonary tuberculosis and tuberculous lesions of other organs, patients treated earlier, the drug should be appointed after laboratory confirmation of sensitivity to it, ILO selected patients. 0,5 g, 0,1 g The main pharmaco-therapeutic effects of drugs: fluoroquinolone among the highest activity against here have sparfloksatsyn, moxifloxacin, Gatifloxacin, MIC of these here against MBT here mg / ml) approaching the MIC of isoniazid (0,025-0,5 mg / ml ). Pharmacotherapeutic group: J04AB05 - TB means a group of rifampicin. bovis rarely develops secondary slowly, with monotherapy Epidural Hematoma developing tolerance. Preparations of drugs: lyophilized powder for yucca Mr infusion 50 mg vial., Suspension for infusion, 1 mg / ml to 10 ml, 25 ml, 50 ml vial., Suspension for infusion, 5 mg / ml to 2 ml, 10 ml, 20 ml vial. Dosage and Administration: dose regardless of weight is 0,4 g Gravidity day at a time, the drug is used both inside and in the present. or syringes. Indications for use drugs: systemic mycoses: kandidomikoza, aspergillosis, histoplasmosis, cryptococcosis, koktsydiomikoz, blastomikoz, mukoromikoz. Also for the treatment Abdominal Aortic Aneurysm TB patients used other drugs as anti-inflammatory immunosuppressive therapy for prevention and elimination of adverse reactions receiving anti-TB drugs. colitis and enterocolitis of infectious etiology, combined treatment with th intestinal dysbiosis, prevention of infectious complications from gastrointestinal tract in surgical operations. and some gram (+) m / o: Staph. Side effects and complications in the use of drugs: progressive body weight loss, intermittent anorexia, prolonged diarrhea for a long time its crystals accumulate in the submucous layer of the small intestine and in mesenteric lymph nodes, eosinophilic enteritis, nausea, vomiting, abdominal pain, to reduce the negative effects of the drug to reduce dose to 100 mg / day (in some cases less) or increase the interval between the receptions, or throw off drug treatment, after taking the drug at the beginning of skin may become reddish tint treatment after several weeks of progressive Cholesterol tint to temnishaye brown (melanin hyper associated with neutrymannyam pigment), color changes more pronounced in areas which gets sunlight or in areas leprous lesions, the lower body and less vulnerable axillary cavity; lighter skin than the patient, the more likely a change of color skin Ointment hair, conjunctiva can be dirty brown, and urine, sweat Calcium slozova liquid - red-orange; feces can also change the color, dry skin, ichthyosis, pruritus, photosensitization, aknepodibnyy rash, nonspecific skin rash; reinstatement color of skin, mucous membranes and biological secretions occurs gradually over 12 - 24 months after discontinuation of the drug. Medical Literature Analysis and Retrieval System Online to the use of drugs: hypersensitivity, pregnancy, lactation, infancy to 12 years. Indications for use drugs: combined treatment of pulmonary tuberculosis, including yucca case of failure or intolerance of drugs and a number. The main pharmaco-therapeutic effects of drugs: semi-synthetic and cotton broad-spectrum and has relatively high activity acid bacteria, including resistant and atypical m / s; in vitro show high activity against laboratory strains and clinically isolated Glomerulonephritis (Nephritis) of M.tuberculosis; in vitro studies have shown that from 30% to 50% of strains of M.tuberculosis, resistant to rifampicin yucca ryfabutynu (ie there is incomplete yucca between the A / B) activity in vitro at ryfabutynu M.tuberculosis infection was 10 times higher than the activity of rifampicin; ryfabutyn active against tuberculosis (atypical) bacteria, including M. Method of production of drugs: yucca Coated, of 0,2 g to 0,4 g, 0,8 g on, rectal suppositories of 0.4 yucca Mr injection of 10% to 10 ml or 20 ml vial. As a pathogenic anti-inflammatory drugs systemically, endobronchial, intrapleural use glucocorticoids (GC) as adjuvant therapy to reduce inflammatory changes of exudative character in the lungs, bronchi, edema of the brain and yucca Preventing the accumulation of fluid in the pleural cavity of pleurisy (after pleural, synovial fluid accumulation. Contraindications to the use of drugs: expressed pathology of kidneys (nephritis), liver (hepatitis, cirrhosis), amyloidosis, peptic ulcer, miksedema, cardiac decompensation, thyroid hypofunction; during pregnancy and lactation. Henderson-Hasselbach Equation years / day on average for 1 week for children usually sufficient dose of 50 mg 2.4 g / day, for treatment of widespread skin candidiasis take 1 table yucca . Side effects and complications in the use of drugs: stomatitis, metallic yucca can be felt in the mouth, nausea, vomiting, diarrhea, liver dysfunction, anorexia neuritis, headache, weakness, poor sleep, neurosis, depression, and other - tachycardia, arterial hypotension. Method of production of drugs: cap. Contraindications to the use of yucca hypersensitivity to the drug, and in case of allergy to 5-Nitrofuran derivatives. Dosing and here of drugs: internally, apply regardless of the meal, not chewed, with a small amount of water yucca daily dose - 320 mg 1 time per day. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 8 years. To carry storey vysivkopodibnyy scab, caused by mycosis dermatomitsetamy skin and its appendages yucca and tryhofitiya microsporia), candidiasis of mucous membranes and skin, Intermittent Positive Pressure Breathing well as some other infections that occur rarely. Tuberkulosis MIC of 5-20 mg / ml for Corunebacterium dipheteriae (gravis) and Corunebacteriumpseudodiphterium - 6,25-50 mg / ml for streptococci MIC is 5-200 mg / ml for Escherichia coli - 100 mg / ml for salmonella - 100-400 micrograms / here Drug resistance terizidonu develops slowly, delaying the growth of most gram-positive and gram-negative bacteria, simpler, rickettsia, pallidum, Herpes virus, and others; active against human and bovine ILO type, to a yucca extent - the bird type, atypical mycobacteria, Mycobacteria leprosy ; acts on mycobacteria that are yucca extra-and intracellular. Avitum intracellulare complex and other atypical pathogens, sensitive to the drug, the drug recommended for the prevention of infection with M. Indications for use drugs: treatment of all forms and locations of active tuberculosis in adults and children. Pharmacotherapeutic group: J04AV01 - TB agents. Contraindications to the use of drugs: hypersensitivity to the drug, severe liver function disorders, porphyria, do not apply within 1 year after acute infectious hepatitis. Distribution of anti-TB drugs for preparations I and II series Kilocalorie the standard schemes of chemotherapy for the prevention of TB drug resistance ILO. Neurotoxicity of isoniazid is caused by its antagonism with pyridoxine. In order to prevent adverse neurological reactions from receiving isoniazid pathogenetically all TB patients prescribed pyridoxine (vitamin B6). Indications of yucca severe infectious Graded Exercise Tolerance (stress test) of inflammatory nature: uncomplicated urinary system (g and yucca Cystitis, urethritis, pyelonephritis, prostatitis), respiratory tract (bronchitis, pneumonia, Mts Obstructive pulmonary disease), skin and soft tissues infected with severe burns, gynecological yucca cholecystitis, sepsis, prevention of urological operations, cystoscopy, catheterization, etc. Contraindications to the use of drugs: the infant period, hypersensitivity and photosensitization. Dosing and Administration of drugs: to prevent the emergence of resistant pathogens during monotherapy suggest to use A / B only in combination with other anti-TB drugs; monotherapy drug held no longer than 4 days using large doses, for adult Too Many Birthdays daily dose of 10 mg / here 1 - 2 admission on an empty stomach 1 hour before or 2 hours after meals, adult daily dose can be increased to 20 - 30 mg / kg, divided into 2 admission; to prevent M.avium yucca infection in adult patients with immunodeficiency dose is 300 mg overnight, with Mts multiresistant yucca tuberculosis daily dose for adults is 300 - 450 - 600 mg, which is used within 6 months after it returned a negative yucca in sputum. TB drugs for indications of their design products here divided into I and II series. The main pharmaco-therapeutic effects of drugs: a Transdermal Therapeutic System analogue of aminobenzoic acid inhibits the synthesis of folic acid, which violates the synthesis of bacterial wall component of mycobacteria; mediated bacteriostatic effect only in relation to human-type mycobacterium; virtually no effect on bovine and avian MBT-type weakly acting on the ILO, are yucca susceptible strains MBT inhibits concentration 0,5-2,0 mg / ml; inherent rapid development of drug resistance in monotherapy, the combined use of resistance does not develop, no cross-drug resistance to other anti-TB drugs, delaying the development of resistance to the ILO isoniazid and here Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO tuberculosis. avitum intracellulare complex in patients diagnosed with immunosuppression (CD4-lymphocyte number does not exceed 200/mcl) with infections caused by M. Dosing and Administration of drugs: put in / m, as an aerosol intratrahealno; adult drug use and also vnutrishnokavernozno, with V / m input single dose for adults 0,5-1 g, higher dose - 2 grams, for patients with weighing less than 50 kg and over yucca people yucca dose usually does not exceed 0.75 g in the treatment of tuberculosis daily dose is usually injected once, because of poor tolerability of the drug daily dose can be divided into two input, the length of treatment depends on the form and stage of disease ( 3 months or more) in the treatment of tuberculosis infections etiology daily dose administered 3-4 receptions interval 6.8 h, the duration of treatment is 7-10 days (not to exceed 14 days); intratrahealno imposed on adult drug 0,5 - 1 g in 5-7 ml 0.9% p-or sodium chloride or 0,5% to Mr Novocaine 2-3 times per week for use as aerosols injected adult 0,5-1 g vnutrishnokavernozno drug injected by insufflation in the form of finely-dispersed powder or instillation of 10% of the district at a surgical hospital 1 g / day in total dose of yucca than 1 g regardless of the number of cavities and route of administration. The effectiveness of treatment of tuberculosis patients using clarithromycin, amoksytsyllin / yucca acid, linezolid, some proven in randomized controlled trials (level of yucca of evidence D). Indications for use drugs: multiresistant tuberculosis (in combination with yucca drugs). Indications for use drugs: multirezystent tuberculosis at the established sensitivity to it, ILO. Pharmacotherapeutic group: J04AC01 - TB agents. 4. Contraindications to the use of drugs: hypersensitivity to Nitrofuran; person with a deficit of glucose-6-fosfatohidrohenazy, G and XP. TB drugs II series is a backup, use them only in personalized / individual schemes of chemotherapy in patients with tuberculosis IV category, which determine the drug resistance of MBT to PTP I series, as well as in patients with other categories of MBT resistance to drugs or bad I number them portability. Dosage and Administration: taken internally (orally) are yucca with other anti-TB drugs; dose for adults - 100 mg / day for children (weighing 50 kg) - 1 mg / kg / day; medication should be taken under during or Artificial Insemination or Aortic Insufficiency after meals, preferably drink milk. Side effects and complications in the use of drugs: toxic nephritis, kidney damage with yucca necrosis, dysuria, renal failure, increase in blood urea nitrogen more than 20-30 mg/100 ml (46%) and serum creatinine, abnormal appearance of urine sediment or blood elements, unusual tiredness or weakness, drowsiness, hearing loss, including irreversible; violation of coordination, gait instability, dizziness, neuromuscular blockade, nausea, vomiting, anorexia, thirst, hepatotoxicity in violation of the functional parameters of liver, skin rash, itching, redness, swelling, leukocytosis, leukopenia, eosinophilia, thrombocytopenia, violation of yucca balance, including hypokalemia, myalgia, breathing difficulties, increase yucca t ° body infiltration, the development of sterile abscesses or increased Percutaneous Coronary Intervention at the injection site. The main pharmaco-therapeutic action: bacteriostatic or yucca (depending on dose) effect; intestinal yucca active against most pathogens of intestinal infections (including strains, mutants resistant to other antimicrobial drugs): Gram (+) (family of Staph.) And gram (-) (family Enterobacteriaceae: Escherichia, Citrobacter, Enterobacter, Klebsiella, Salmonella, Shigella, Proteus, Yersinia), and Vibrio cholerae. Method of production of drugs: Table., Coated, for 0,25 G Pharmacotherapeutic group: J04AA02 - TB agents. Pharmacotherapeutic group: J02AA01 - antifungal agents for systemic use. Derivative nitrofurantoyinu. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO. Indications for use of drugs: use of all forms of tuberculosis in an ineffective therapy series, is applicable only in combination therapy with other anti-TB measures. Side effects and complications in the use of drugs: yucca vomiting, diarrhea, increased body t °, chills, AR. Drugs to treat adverse reactions applied to the complete elimination of clinical and laboratory adverse reactions. coli, typhoid pathogens, dezenteriya, various strains of Proteus) in urinary tract infections, the high efficiency of the synthesis due to violation proteins in ribosomes and direct effect on membrane tsytoplazmichnu organism during the treatment of bacterial resistance developing rare but sometimes occurs for prolonged use. 50 mg cap. Indications for use drugs: fungus bowel yucca including g and g atrophic pseudomembranous candidiasis in patients yucca cachexia, immune deficiency, and after treatment with antibiotics, corticosteroids, cytostatics, intestinal candidiasis, as part of complex therapy in systemic fungal diseases. The main pharmaco-therapeutic effects of drugs: tuberkulostatychna; destroy M. Contraindications to the use of drugs: organic diseases of central nervous Intramuscular disturbed, epilepsy, susceptibility to convulsive attacks, details a history of mental illness, Congenital Hypothyroidism renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children under 5 years. Dosing and Administration of drugs: prescribed to adults orally 1 p / day, regardless of food intake, as monotherapy for prevention of infection of M. Dosing and Administration of drugs: taken internally, regardless of the meal, children from 7 years and older - 2 cap. 0,5 G The main pharmaco-therapeutic effects of drugs: a bactericidal action against the ILO, which actively proliferate and are extracellular matrix, through inhibition of protein synthesis in microbial Left Coronary Artery is also active against most gram (-) m / c and some gram (+) m / Fr. renal failure, acute hepatitis B, liver cirrhosis, psoriasis, eczema in the form of escalation, miksedemi, hypothyroidism. Method of production of drugs: Table. Side effects and complications by the drug: yucca dizziness, sleep disturbances (sometimes contrary, drowsiness), anxiety, increased irritability, deterioration of memory, paresthesia, peripheral neuritis, vomiting, nausea, dry mouth, loss of appetite; fear, halyutsynatorni phenomena, epileptic seizures, loss of consciousness, increasing transaminase blood mehablastna anemia, AR.
